Taiho Oncology, Inc.
Clinical trials sponsored by Taiho Oncology, Inc., explained in plain language.
Now part of
Otsuka Holdings Co., Ltd.
4578
TOKYO
A subsidiary of Otsuka Holdings focused on oncology treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cancer cocktail shows promise in early trial Results expected Oct 2026 (estimated)
- New study checks if kidney disease affects cancer drug safety Results expected Dec 2026 (estimated)
- New targeted drug shows promise for rare bile duct cancer Results expected Dec 2026 (estimated)
- New study seeks safer dosing of cancer drug for patients with liver issues Results expected Dec 2026 (estimated)
- Cancer drug futibatinib gets a safety check in Long-Term rollover study Results expected Apr 2027 (estimated)